Search
引用資料與參考文獻 (1)
Invitrogen™
LentiArray™ CRISPR Negative Control Lentivirus, human, non-targeting
Negative control gRNAs are essential in screening applications for setting thresholds for hit determination. The Invitrogen™ LentiArray™ CRISPR Negative Control深入閱讀
| 產品號碼 | Quantity |
|---|---|
| A32062 | 100 μL |
產品號碼 A32062
價格 (TWD)
14,910.00
線上優惠
Ends: 31-Dec-2025
21,300.00您節省 6,390.00 (30%)
Each
Quantity:
100 μL
價格 (TWD)
14,910.00
線上優惠
Ends: 31-Dec-2025
21,300.00您節省 6,390.00 (30%)
Each
Negative control gRNAs are essential in screening applications for setting thresholds for hit determination. The Invitrogen™ LentiArray™ CRISPR Negative Control Lentivirus, Human Scrambled, contains a gRNA sequence with no sequence homology to any region of the human genome.
For Research Use Only. Not for use in diagnostic procedures.
規格
Control TypeNon-targeting negative control
Delivery TypeLentiviral
For Use With (Application)CRISPR gene knockout
Product LineLentiArray
Product TypeCRISPR Negative Control Lentivirus
Quantity100 μL
Shipping ConditionDry Ice
PromoterU6
SpeciesHuman
Transfection TechniqueLentiviral transduction
Unit SizeEach
內容物與存放
1 x 100 μL. Store at -68 to -85°C.
引用資料與參考文獻 (1)
引用資料與參考文獻
Abstract
A functional screening of the kinome identifies the Polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain.
Journal:Pediatr Blood Cancer
PubMed ID:28398638
Malignant rhabdoid tumors (MRTs) are deadly embryonal tumors of the infancy. With poor survival and modest response to available therapies, more effective and less toxic treatments are needed. We hypothesized that a systematic screening of the kinome will reveal kinases that drive rhabdoid tumors and can be targeted by specific